| Identification | Back Directory | [Name]
1H-Benzimidazole-5-carboxamide, 1-[4-[5-(aminocarbonyl)-2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-3H-thieno[2,3-d]imidazol-3-yl]-2-buten-1-yl]-2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-7-[3-(4-morpholinyl)propoxy]- | [CAS]
2653337-73-4 | [Synonyms]
STING agonist-9
1H-Benzimidazole-5-carboxamide, 1-[4-[5-(aminocarbonyl)-2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-3H-thieno[2,3-d]imidazol-3-yl]-2-buten-1-yl]-2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-7-[3-(4-morpholinyl)propoxy]- | [Molecular Formula]
C39H47N13O6S | [MOL File]
2653337-73-4.mol | [Molecular Weight]
825.94 |
| Hazard Information | Back Directory | [Uses]
STING agonist-9 (Compound 45) is a potent STING agonist with an EC50 of 1.2 nM and 32.82 μM against h-STING and m-STING, respectively. STING agonist-9 shows antitumor activity[1]. | [in vivo]
STING agonist-9 (Compound 45) significantly inhibits the tumor growth in allograft 4T1 and CT26 tumor models by systemic administration, and induces tumor regression in CT26 tumor model without inducing weight loss[1]. | [References]
[1] Niu J, et al. Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration. Eur J Med Chem. 2022 Aug 5;238:114482. DOI:10.1016/j.ejmech.2022.114482 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|